NO971829L - Peptidspesifisitet av antimyelin basisprotein og administrering av myelin basisproteinpeptider til pasienter med multippel sklerose - Google Patents

Peptidspesifisitet av antimyelin basisprotein og administrering av myelin basisproteinpeptider til pasienter med multippel sklerose

Info

Publication number
NO971829L
NO971829L NO971829A NO971829A NO971829L NO 971829 L NO971829 L NO 971829L NO 971829 A NO971829 A NO 971829A NO 971829 A NO971829 A NO 971829A NO 971829 L NO971829 L NO 971829L
Authority
NO
Norway
Prior art keywords
mbp
basic protein
administration
residues
amino acid
Prior art date
Application number
NO971829A
Other languages
English (en)
Other versions
NO971829D0 (no
NO321385B1 (no
Inventor
Kenneth G Warren
Ingrid Catz
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Publication of NO971829D0 publication Critical patent/NO971829D0/no
Publication of NO971829L publication Critical patent/NO971829L/no
Publication of NO321385B1 publication Critical patent/NO321385B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19971829A 1994-10-21 1997-04-21 Peptider eller salter derav, farmasoytisk preparat omfattende et peptid eller et salt derav samt deres anvendelse. NO321385B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/327,357 US5817629A (en) 1991-10-22 1994-10-21 Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
PCT/CA1995/000583 WO1996012731A1 (en) 1994-10-21 1995-10-20 Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients

Publications (3)

Publication Number Publication Date
NO971829D0 NO971829D0 (no) 1997-04-21
NO971829L true NO971829L (no) 1997-06-23
NO321385B1 NO321385B1 (no) 2006-05-02

Family

ID=23276218

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971829A NO321385B1 (no) 1994-10-21 1997-04-21 Peptider eller salter derav, farmasoytisk preparat omfattende et peptid eller et salt derav samt deres anvendelse.

Country Status (19)

Country Link
US (2) US5817629A (no)
EP (1) EP0789709B1 (no)
AT (1) ATE201415T1 (no)
AU (1) AU713546B2 (no)
CA (1) CA2203018A1 (no)
CZ (1) CZ292454B6 (no)
DE (1) DE69521055T2 (no)
DK (1) DK0789709T3 (no)
ES (1) ES2159322T3 (no)
FI (1) FI120308B (no)
HU (1) HU217633B (no)
NO (1) NO321385B1 (no)
NZ (1) NZ293910A (no)
PL (1) PL182508B1 (no)
RO (1) RO117096B1 (no)
RU (1) RU2157815C2 (no)
SK (1) SK282463B6 (no)
UA (1) UA55375C2 (no)
WO (1) WO1996012731A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US20020111312A1 (en) * 1991-10-22 2002-08-15 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6251396B1 (en) * 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US20030191063A1 (en) * 2000-08-21 2003-10-09 Wraith David Cameron Peptide selection method
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
US7560529B2 (en) 2001-04-24 2009-07-14 FDS Pharma Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
EP1390497A2 (en) 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
CA2501318A1 (en) * 2002-10-10 2004-04-22 Yeda Research And Development Co. Ltd Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
RU2333219C2 (ru) 2003-02-14 2008-09-10 Провид Фармасьютикалз, Инк. Ингибиторы представления антигенов молекулами мнс ii класса и способы их применения
US20080221115A1 (en) * 2007-02-26 2008-09-11 Liat Hayardeny-Nisimov Use of long-chain alcohol derivatives for the treatment of alopecia areata
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
CN101848725B (zh) 2007-10-31 2013-05-22 艾匹托普技术(布里斯托尔)有限公司 组合物
US20110217324A1 (en) * 2007-12-03 2011-09-08 Olson Gary L Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641474A (en) 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5869054A (en) 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US6039947A (en) 1987-06-24 2000-03-21 Autoimmune, Inc. Peptides derived from immunodominant epitopes of myelin basic protein
JP2512796B2 (ja) 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド 自己抗原の経口投与による自己免疫疾患の治療法
US5645820A (en) 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571499A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
CA1340012C (en) * 1987-08-17 1998-08-25 Trustees Of Leland Stanford Jr. University Peptide determinant associated with immunity
US5858980A (en) 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
IL165071A (en) 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
WO1993021222A1 (en) * 1992-04-09 1993-10-28 Autoimmune, Inc. Suppression of t-cell proliferation using peptide fragments of myelin basic protein
AU5360796A (en) 1995-03-09 1996-10-02 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
US5935577A (en) 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate

Also Published As

Publication number Publication date
NO971829D0 (no) 1997-04-21
EP0789709B1 (en) 2001-05-23
DE69521055T2 (de) 2001-11-22
FI971662A0 (fi) 1997-04-18
ES2159322T3 (es) 2001-10-01
AU713546B2 (en) 1999-12-02
AU3647895A (en) 1996-05-15
PL319835A1 (en) 1997-09-01
NZ293910A (en) 1999-07-29
SK282463B6 (sk) 2002-02-05
US6258781B1 (en) 2001-07-10
EP0789709A1 (en) 1997-08-20
DE69521055D1 (de) 2001-06-28
HU217633B (hu) 2000-03-28
CA2203018A1 (en) 1996-05-02
PL182508B1 (pl) 2002-01-31
HUT76977A (hu) 1998-01-28
WO1996012731A1 (en) 1996-05-02
US5817629A (en) 1998-10-06
FI971662A (fi) 1997-06-17
CZ292454B6 (cs) 2003-09-17
CZ116997A3 (en) 1997-10-15
SK49297A3 (en) 1997-11-05
RO117096B1 (ro) 2001-10-30
FI120308B (fi) 2009-09-15
UA55375C2 (uk) 2003-04-15
RU2157815C2 (ru) 2000-10-20
ATE201415T1 (de) 2001-06-15
NO321385B1 (no) 2006-05-02
DK0789709T3 (da) 2001-09-10

Similar Documents

Publication Publication Date Title
NO971829L (no) Peptidspesifisitet av antimyelin basisprotein og administrering av myelin basisproteinpeptider til pasienter med multippel sklerose
EP0662827A4 (en) THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS BASED ON NOTCH PROTEINS AND NUCLEIC ACIDS.
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
FI941860A (fi) Keskushermoston pesäkekovettumatautiaivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin synteettinen peptidispesifisyys
WO1995030435A3 (en) Compositions and treatment for multiple sclerosis
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
CY1108239T1 (el) Θραυσματα πεπτιδιου της βασικης πρωτεϊνης της μυελινης, οι φαρμακευτικες τους συνθεσεις και η χρηση τους στη θεραπεια της σκληρυνσης κατα πλακας
NZ335835A (en) Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees